Fabio Massaiti Iwamoto, MD
Neurology · New York
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Trustees of Columbia University in the City of New York · 2,262 clinicians in this group
Hospitals listed: New York-Presbyterian Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Iwamoto’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- New York-Presbyterian HospitalNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of New York Presbyterian Healthcare System, which runs 8 hospitalsHome of Herbert Irving Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 15.2 (13.8 to 16.7) · 1,897 cases, Jan 2024 – Dec 2024Better than the national rate — Abdominopelvic accidental puncture or laceration rate: 0.35 (0 to 0.86) · 10,364 cases, Jul 2022 – Jun 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.4 (0.3 to 0.51), Jul 2022 – Jun 2024Better than the national rate — In-hospital fall-associated fracture rate: 0.14 (0.03 to 0.25) · 52,654 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 1.48 (0.6 to 2.36) · 14,926 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative acute kidney injury requiring dialysis rate: 0.48 (0 to 1.06) · 8,078 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative hemorrhage or hematoma rate: 0.94 (0.21 to 1.66) · 12,529 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 6.15 (4.51 to 7.79) · 8,277 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 1.66 (0.42 to 2.91) · 8,436 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.09 (0 to 0.3) · 44,511 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.575, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.632, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.22, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.743, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.6 (2.9 to 4.4) · 1,897 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.6 (8.9 to 12.6) · 7,950 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.6 (0.6 to 0.7) · 4,225 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for New York-Presbyterian Hospital
Behind the star rating — Deaths: 6 better, 2 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 6 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 15.2 (13.8 to 16.7) · 1,897 cases | Worse | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.35 (0 to 0.86) · 10,364 cases | Better | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.4 (0.3 to 0.51) | Better | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.14 (0.03 to 0.25) · 52,654 cases | Better | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 1.48 (0.6 to 2.36) · 14,926 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.48 (0 to 1.06) · 8,078 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 0.94 (0.21 to 1.66) · 12,529 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.15 (4.51 to 7.79) · 8,277 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 1.66 (0.42 to 2.91) · 8,436 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.09 (0 to 0.3) · 44,511 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.575 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.632 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.22 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.743 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.6 (2.9 to 4.4) · 1,897 cases | Better | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.6 (8.9 to 12.6) · 7,950 cases | Better | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.6 (0.6 to 0.7) · 4,225 cases | Better | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.83 (135.92 to 177.74) · 798 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 382 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.7 · 574 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 616 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.9 · 2,532 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.9 · 3,140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 7.7 · 1,821 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 1.8 · 24,470 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.22) · 48,588 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 0.84 (0 to 1.9) · 3,187 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 1,240 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.314 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 1,045 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.4 · 5,234 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 11 · 686 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3 · 2,938 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.4 · 3,258 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 5,005 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 1,230 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 411 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 1,226 cases | None | Jul 2023 – Jun 2025 |
What patients said (2,640 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$82,582
Medicare paid this office $82,582 for 114 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 83 | $57,293 | $165 |
| Return visit (30+ min) | 52 | $11,166 | $119 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 104 | $6,860 | $15 |
| New patient visit (60+ min) | 13 | $2,748 | $211 |
| Short return visit (20+ min) | 12 | $2,435 | $81 |
Who their Medicare patients are
114 Original Medicare patients in 2024. Average age 70 · Women 47% · Also on Medicaid 23% · Health risk score 2.05. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 61% · Stroke 33% · Diabetes 30% · Depression 24% · Coronary heart disease 18% · Cancer 18% · Chronic kidney disease 17% · Atrial fibrillation 16% · Heart failure 15% · Dementia 13% · COPD 11%.
The office billed $376,220, Medicare allowed $104,249 and paid $82,582; for 1,119 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 114 | 1,119 | 70 | 2.05 | $376,220 | $82,582 |
| 2023 | 108 | 448 | 69 | 1.85 | $301,580 | $64,539 |
| 2022 | 112 | 495 | 69 | 1.73 | $325,000 | $68,515 |
| 2021 | 99 | 513 | 69 | 1.55 | $269,590 | $66,649 |
| 2020 | 85 | 427 | 69 | 1.57 | $191,370 | $45,341 |
| 2019 | 94 | 378 | 70 | 1.94 | $169,835 | $36,740 |
| 2018 | 98 | 456 | 67 | 1.89 | $210,875 | $43,908 |
| 2017 | 100 | 483 | 68 | 2.04 | $220,450 | $45,665 |
| 2016 | 94 | 464 | 66 | 1.63 | $185,750 | $42,942 |
| 2015 | 91 | 397 | 70 | 2.34 | $151,850 | $39,729 |
| 2014 | 76 | 328 | 71 | 2.02 | $128,268 | $31,963 |
| 2013 | 99 | 539 | 68 | 1.93 | $247,450 | $55,139 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 79 | $47,958 | $156 |
| Return visit (30+ min) | 35 | $7,086 | $118 |
| New patient visit (60+ min) | 20 | $4,097 | $195 |
| Short return visit (20+ min) | 16 | $3,432 | $84 |
2022: 4 services
| Long return visit (40+ min) | 82 | $46,669 | $156 |
| Return visit (30+ min) | 53 | $10,995 | $107 |
| New patient visit (60+ min) | 21 | $4,121 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,278 | $175 |
2021: 4 services
| Long return visit (40+ min) | 54 | $28,019 | $170 |
| Return visit (30+ min) | 71 | $25,627 | $116 |
| Short return visit (20+ min) | 34 | $7,459 | $79 |
| New patient visit (60+ min) | 21 | $4,289 | $204 |
2020: 4 services
| Return visit (30+ min) | 64 | $20,484 | $96 |
| Long return visit (40+ min) | 38 | $15,412 | $135 |
| Short return visit (20+ min) | 32 | $5,032 | $70 |
| New patient visit (60+ min) | 17 | $3,311 | $195 |
2019: 4 services
| Return visit (30+ min) | 62 | $23,349 | $95 |
| Short return visit (20+ min) | 14 | $3,657 | $65 |
| Long return visit (40+ min) | 16 | $3,439 | $132 |
| New patient visit (60+ min) | 13 | $2,442 | $188 |
2018: 5 services
| Return visit (30+ min) | 62 | $26,316 | $94 |
| Long return visit (40+ min) | 27 | $4,922 | $126 |
| Short return visit (20+ min) | 20 | $3,231 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $2,460 | $117 |
| New patient visit (60+ min) | 12 | $2,100 | $175 |
2017: 7 services
| Return visit (30+ min) | 61 | $27,473 | $94 |
| Short return visit (20+ min) | 25 | $5,061 | $65 |
| Long return visit (40+ min) | 24 | $4,150 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $4,145 | $180 |
| New patient visit (60+ min) | 16 | $2,688 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,113 | $62 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $664 | $35 |
2016: 3 services
| Return visit (30+ min) | 74 | $27,762 | $91 |
| Long return visit (40+ min) | 28 | $5,656 | $126 |
| Short return visit (20+ min) | 27 | $4,239 | $64 |
2015: 5 services
| Return visit (30+ min) | 56 | $23,215 | $92 |
| Long return visit (40+ min) | 25 | $6,777 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,510 | $180 |
| Short return visit (20+ min) | 18 | $1,919 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $895 | $64 |
2014: 4 services
| Return visit (30+ min) | 56 | $20,090 | $90 |
| Long return visit (40+ min) | 29 | $5,493 | $119 |
| New patient visit (60+ min) | 22 | $3,890 | $177 |
| Short return visit (20+ min) | 20 | $1,949 | $59 |
2013: 7 services
| Return visit (30+ min) | 56 | $23,271 | $92 |
| Long return visit (40+ min) | 42 | $10,808 | $126 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $7,399 | $172 |
| New patient visit (60+ min) | 26 | $4,541 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,414 | $85 |
| Short return visit (20+ min) | 15 | $2,279 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,471 | $61 |
Money from drug and device companies
$2,181 in 2025
| 2025 | 2 | 7 | None | $2,181 |
| 2024 | 3 | 7 | $508 | $9,244 |
| 2023 | 1 | 18 | $7,200 | $8,823 |
| 2022 | 1 | 1 | $578 | $578 |
| 2020 | 2 | 3 | $6,500 | $6,650 |
| 2019 | 2 | 9 | $3,600 | $3,908 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Telix Pharmaceuticals | Illuccix | $2,083 | 6 payments
|
| Caris MPI | Mi Cancer Seek | $97 | 1 payment
|
See all 7 published payments
| Caris MPI | Meals · 2025-11-21 | Mi Cancer Seek | $97 |
| Telix Pharmaceuticals | Meals · 2025-03-08 | Illuccix | $72 |
| Telix Pharmaceuticals | Meals · 2025-03-08 | Illuccix | $63 |
| Telix Pharmaceuticals | Meals · 2025-03-08 | Illuccix | $95 |
| Telix Pharmaceuticals | Travel · 2025-03-08 | Illuccix | $1,320 |
| Telix Pharmaceuticals | Meals · 2025-03-07 | Illuccix | $124 |
| Telix Pharmaceuticals | Travel · 2025-03-07 | Illuccix | $410 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $9,244
| F. Hoffmann-La Roche AG | None | $8,616 | 5 payments
|
| ZOLL Medical | Defibrillator | $508 | 1 payment
|
| Novocure | Optune | $119 | 1 payment
|
2023: $8,823
| Novocure | Optune | $8,823 | 18 payments
|
2022: $578
| Medtronic | None | $578 | 1 payment
|
2020: $6,650
| Merck Sharp & Dohme | None | $5,650 | 2 payments
|
| Novocure | Oncology | $1,000 | 1 payment
|
2019: $3,908
| Novocure | Oncology | $3,715 | 5 payments
|
| Merck Sharp & Dohme | None | $193 | 4 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Phase 1ab Openlabel Master Study of Pf07799544 As A Singleagent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors · 2024 | Their institution | $262,149 |
| Otsuka Pharmaceutical Co., Ltd. · Study of Astx295 in Patients With Solid Tumors With Wild-Type P53 · 2023 | Their institution | $217,646 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2023 | Their institution | $215,626 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2022 | Their institution | $63,052 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2021 | Their institution | $50,072 |
| Novocure GmbH · Ef-41 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune (Ttfields, 200 Khz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma · 2025 | Their institution | $44,344 |
| PFIZER INC. · A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of Pf06840003 in Patients With Malignant Gliomas · 2019 | Their institution | $40,113 |
| E.R. Squibb & Sons, L.L.C. · Ph Iib Cns Lymphoma Mono · 2022 | Their institution | $37,974 |
| TAIHO ONCOLOGY, INC. · Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of Astx295 in Subjects With Wild-Type Tp53 Advanced Solid Tumors · 2024 | Their institution | $37,838 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt · 2020 | Their institution | $32,778 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2024 | Their institution | $31,839 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt (Nivo Mono Rt) - A Randomized Phase 3 Open Label Study of Nivolumab Vs Temozolo Mide Each in Combination With Radiat Ion Therapy in Newly Diagnosed Adult Subjects With Unmethylated Mgmt (Tumor O-6 Methylguanine Dna Meth · 2023 | Their institution | $27,577 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt · 2019 | Their institution | $26,847 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2019 | Their institution | $25,740 |
| Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2025 | Their institution | $17,169 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt - A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Co Mbined With Nivo Lumab Or Placebo in Newly Diagnosed Adult Subjects With Mgmt -Methylated (Tumor O6-Methylguanine Dna Methy · 2022 | Their institution | $15,820 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated (Nivo Mono Chemo Rt) - A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Co Mbined With Nivo Lumab Or Placebo in Newly Diagnosed Adult Subjects With Mgmt -Methylated (Tumor O6-Methylguanine Dna Met · 2023 | Their institution | $13,690 |
| TAIHO ONCOLOGY, INC. · Study of Astx295 in Patients With Solid Tumors With Wild-Type P53 · 2024 | Their institution | $11,110 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2022 | Their institution | $9,820 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2020 | Their institution | $9,620 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib Primary Cns and Testicular Lymphoma (Mono) · 2024 | Their institution | $4,977 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt · 2021 | Their institution | $4,652 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib Primary Cns and Testicular Lymphoma Mono · 2020 | Their institution | $4,248 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib Primary Cns and Testicular Lymphoma Mono · 2021 | Their institution | $2,000 |
| TAIHO ONCOLOGY, INC. · Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of Astx295 in Subjects With Wild-Type Tp53 Advanced Solid Tumors · 2025 | Their institution | $1,386 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib Primary Cns and Testicular Lymphoma Mono · 2019 | Their institution | $628 |
| PFIZER INC. · A Phase 1ab Openlabel Master Study of Pf07799544 As A Singleagent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors · 2023 | Their institution | $404 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1053623934
- Licence
- NY 264009
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-07-08
- NPI last updated
- 2026-07-02
- NPI record certified
- 2026-07-02
This is when the NPI record was last certified, not a medical board exam.